Authorised generics could benefit consumers, US FTC finds
This article was originally published in Scrip
Executive Summary
Competition from authorised generics during an ANDA first-filers' 180-day exclusivity period reduces drug prices, but consumers are harmed when innovators agree not to launch an authorised generic as part of a "reverse payment" patent settlement that also delays the first generic's entry, a US Federal Trade Commission (FTC) report found.